Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Jan 22, 2006 8:15 AM - Dec 31, 2050 12:00 AM

Regulatory Affairs: The IND, NDA, and Post-Marketing


Fundamentals of IND/NDA submissions and Postmarketing Regulatory Requirements

Learn about FDA regulations and expectations for the content, submission, and review of INDs/NDAs and the importance of regulatory strategy. This comprehensive course employs a blend of real-world and interactive lectures, workshops and online precourse modules. This basic to intermediate level training course focuses on prescription drugs and well characterized biological products. The requirements specific to generic drugs, biosimilars, devices, and OTC monograph products are not covered in detail.

What you will learn

  • Fundamentals of the Investigational New Drug (IND) and New Drug Application (NDA) Processes
    • Preparation
    • Content
    • Maintenance and updates
    • Strategy
  • What to expect at meetings and in other interactions with FDA
  • Regulatory Requirements of Prescription Drug Labeling and Advertising
  • Postmarketing Requirements

Who should attend?

  • Regulatory affairs professionals new to the IND/NDA processes
  • Clinical research and development professionals
  • Biostatisticians
  • Basic researchers
  • Quality and manufacturing professionals
  • Medical writers
  • Business professionals
  • Project managers

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Explain the importance of incorporating regulatory strategy into the drug development plan
  • Recognize content and format requirements for INDs/NDAs in the Common Technical Document (CTD) Format
  • Communicate the requirements for submitting INDs/NDAs and amendments and supplements
  • Describe the FDA review processes for evaluating INDs/NDAs
  • Define NDA post-approval responsibilities and requirements
  • Identify regulatory mechanisms to facilitate and expedite new development
  • State how to report adverse events in accordance with current FDA regulations 
  • Apply formal meeting principles and practices when interacting with the FDA
  • Outline the regulatory requirements for prescription drug labeling and advertising

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.